Aims
In the absence of a commonly agreed dosing protocol based on
pharmacokinetic considerations, the dose and treatment duration for
hydroxychloroquine (HCQ) COVID-19 disease currently vary across national
guidelines and clinical study protocols. We have used a model-based
approach to explore the relative impact of alternative dosing regimens
proposed in different dosing protocols for hydroxychloroquine in
COVID-19.